Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | MLL5 |
| Gene Name: | MLL5 |
| Protein Full Name: | Histone-lysine N-methyltransferase MLL5 |
| Alias: | EC 2.1.1.43; HDCMC04P; KMT2E; Myeloid/lymphoid or mixed-lineage leukemia 5; Myeloid/lymphoid or mixed-lineage leukemia 5 (trithorax) |
| Mass (Da): | 204965 |
| Number AA: | 1858 |
| UniProt ID: | Q8IZD2 |
| Locus ID: | 55904 |
| COSMIC ID: | MLL5 |
| Gene location on chromosome: | 7q22.1 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | UNCLEAR |
| Number of cancer specimens: | 20363 |
| Percent of cancer specimens with mutations: | 1.41 |
| Normal role description: | MLL5 is a histone methyltransferase that specifically mono- and dimethylates histone H3 (Lys-4). Involved in cell cycle regulation. Suppresses expression of S-phase genes. Knockdown was shown to induce cell cycle arrest in G1 and G2/M phase cells and overexpression inhibits cell cycle progression. |